UBS Group
VOR icon

UBS Group’s Vor Biopharma VOR Stock Holding History

UBS Group’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.1M Buy
583,666
+90,388
+18% +$1.93M ﹤0.01% 3288
2026
Q2 		$9.08M Buy
493,278
+4,910
+1% +$74.3K ﹤0.01% 3551
2026
Q1 		$8.71M Buy
488,368
+196,250
+67% +$2.77M ﹤0.01% 3507
2025
Q4 		$3.82M Buy
292,118
+216,209
+285% +$4.03M ﹤0.01% 4308
2025
Q3 		$3.7M Sell
75,909
-673
-0.9% -$27.1K ﹤0.01% 4346
2025
Q2 		$2.48M Buy
76,582
+76,159
+18,004% +$673K ﹤0.01% 4587
2025
Q1 		$6.07K Buy
+423
New +$10.2K ﹤0.01% 8932
2024
Q3 		– Sell
-560
Closed -$11.2K – 10108
2024
Q2 		$11.2K Sell
560
-1,359
-71% -$44K ﹤0.01% 7657
2024
Q1 		$91K Buy
1,919
+22
+1% +$966 ﹤0.01% 6270
2023
Q4 		$85.3K Buy
1,897
+1,079
+132% +$44.5K ﹤0.01% 6266
2023
Q3 		$34.7K Buy
818
+307
+60% +$16.6K ﹤0.01% 6518
2023
Q2 		$31.6K Buy
+511
New +$46.7K ﹤0.01% 6691
2023
Q1 		– Sell
-204
Closed -$27.2K – 10438
2022
Q4 		$27.2K Buy
+204
New +$20.2K ﹤0.01% 7347
2022
Q3 		– Sell
-43
Closed -$4K – 10975
2022
Q2 		$4K Buy
+43
New +$4.4K ﹤0.01% 9146
2022
Q1 		– Sell
-358
Closed -$83K – 10956
2021
Q4 		$83K Buy
358
+356
+17,800% +$103K ﹤0.01% 6475
2021
Q3 		$1K Sell
2
-254
-99% -$75.5K ﹤0.01% 9256
2021
Q2 		$95K Sell
256
-99
-28% -$48.8K ﹤0.01% 5920
2021
Q1 		$306K Buy
+355
New +$300K ﹤0.01% 5194

Other funds holding VOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
NEXTBio Capital Management
NEXTBio Capital Management Menlo Park, California $234M AUM 176.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

UBS Group's VOR Position: Q3 2026 in Review

UBS Group increased its Vor Biopharma (VOR) stake by 18% in Q3 2026, buying an estimated $1.93M and bringing the position to 583,666 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3288.

UBS Group first reported a position in VOR in Q1 2021 and has held it in 18 quarters since. 98 funds tracked by Wall St. Rank hold VOR as of Q3 2026.

  • UBS Group held 583,666 shares of Vor Biopharma worth $11.1M as of Q3 2026.
  • UBS Group bought 90,388 Vor Biopharma shares in Q3 2026, an estimated $1.93M.
  • Vor Biopharma made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #3288 holding.
  • UBS Group first reported a position in Vor Biopharma in Q1 2021 and has held it in 18 quarters since.
  • 98 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.